ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.24 and traded as low as $0.1035. ProPhase Labs shares last traded at $0.1198, with a volume of 56,021 shares trading hands. Wall Street Analyst Weigh In
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.42 and traded as low as $0.1402. ProPhase Labs shares last traded at $0.1503, with a volume of 146,678 shares changing hands. Wall Street Analyst Weigh
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential UNIONDALE, NY, April 15, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today reported its financial results for the year ended December 31, 2025 and provided a business update highlighting continued advancement and expansion of its Crown Medical Collections initiative. “We are very encouraged by the scale and progression of activity across our receivables platform,” said Ted Karkus, Chief Executive Officer of ProPhase Labs.
Shares of ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares traded. Analysts Set New Price Targets
Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided a business update regarding its Crown Medical Collections initiative and related strategic activities.
Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative, with each initiative independently offering the potential to drive significant liquidity and materially strengthen the Company's balance sheet.
UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.12 and traded as low as $0.1740. ProPhase Labs shares last traded at $0.1998, with a volume of 490,748 shares traded. Analyst Upgrades and Downgrades Several equities
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.26 and traded as low as $0.1661. ProPhase Labs shares last traded at $0.2799, with a volume of 1,509,825 shares changing hands. Analyst Ratings Changes Several research
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base.
